BioNTech (NASDAQ:BNTX) Shares Gap Down to $100.53

BioNTech SE (NASDAQ:BNTX)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $100.53, but opened at $96.38. BioNTech shares last traded at $100.39, with a volume of 166,704 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on BNTX shares. HC Wainwright restated a “buy” rating and set a $113.00 price objective on shares of BioNTech in a report on Tuesday, August 27th. Deutsche Bank Aktiengesellschaft upgraded shares of BioNTech from a “hold” rating to a “buy” rating and set a $95.00 price objective on the stock in a report on Wednesday, August 7th. TD Cowen reduced their price objective on shares of BioNTech from $98.00 to $85.00 and set a “hold” rating for the company in a report on Tuesday, August 6th. Hsbc Global Res upgraded shares of BioNTech from a “hold” rating to a “strong-buy” rating in a report on Friday, August 2nd. Finally, JPMorgan Chase & Co. cut their price objective on shares of BioNTech from $94.00 to $91.00 and set an “underweight” rating on the stock in a report on Thursday, August 15th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $109.09.

BioNTech Stock Performance

The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40. The firm has a market capitalization of $23.60 billion, a PE ratio of 198.54 and a beta of 0.23. The company’s fifty day simple moving average is $85.91 and its 200 day simple moving average is $89.37.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The business had revenue of $128.70 million for the quarter, compared to analysts’ expectations of $134.98 million. During the same quarter in the previous year, the company posted ($0.86) earnings per share. The business’s quarterly revenue was down 23.3% compared to the same quarter last year. As a group, equities research analysts expect that BioNTech SE will post -2.8 EPS for the current fiscal year.

Hedge Funds Weigh In On BioNTech

A number of large investors have recently made changes to their positions in BNTX. Harding Loevner LP bought a new stake in BioNTech during the 4th quarter worth approximately $410,984,000. Candriam S.C.A. increased its holdings in shares of BioNTech by 261.2% in the second quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after purchasing an additional 418,695 shares during the period. Point72 Asset Management L.P. raised its position in shares of BioNTech by 283.5% in the second quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock worth $37,103,000 after buying an additional 341,311 shares in the last quarter. Primecap Management Co. CA boosted its stake in BioNTech by 2.8% during the fourth quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock valued at $502,735,000 after buying an additional 131,490 shares during the period. Finally, SG Americas Securities LLC grew its position in BioNTech by 610.5% during the first quarter. SG Americas Securities LLC now owns 70,143 shares of the company’s stock worth $6,471,000 after buying an additional 60,270 shares in the last quarter. 15.52% of the stock is owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.